This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Brooks, G. Articles by Hearse, D. J. Search for Related Content PubMed Articles by Brooks, G. Articles by Hearse, D. J.

(Circulation Research. 1996;79:628-631.)
© 1996 American Heart Association, Inc.

Articles

Role of Protein Kinase C in Ischemic Preconditioning: Player or Spectator?

Gavin Brooks, David J. Hearse

Cardiovascular Research, The Rayne Institute, St Thomas' Hospital, London, SE1 7EH, UK.

Correspondence to Dr Gavin Brooks, Cardiovascular Research, The Rayne Institute, St Thomas' Hospital, London, SE1 7EH, UK.

Key Words: protein kinase C • ischemic preconditioning • Downey hypothesis • Editorials

	Introduction

 
Although it may be debatable whether preconditioning will ever fulfill its clinical expectations, the hope that a new therapeutic modality may emerge from this fascinating phenomenon has given great impetus to the search for its underlying mechanism. Preconditioning is unquestionably a powerful phenomenon, it is readily and consistently demonstrable under many experimental conditions, and it has just celebrated its 10th birthday.¹ In view of all this, it is perhaps surprising that the precise mechanism of preconditioning remains elusive and recently has become the subject of controversy.

An observer of the preconditioning literature could, at first sight, be forgiven for concluding that the precise mechanism is established and that protein kinase C (PKC) activation is a pivotal common factor that links a spectrum of receptor-mediated triggers of preconditioning. Downey and colleagues, now supported by other investigators (reviewed in References 2 and 3),^{2 3} have developed the compelling hypothesis that stimulation of a variety of G protein–coupled receptors (eg, adenosine A₁, ₁-adrenergic, muscarinic, bradykinin, and endothelin-1 receptors) results in the activation of PKC. This, in turn, leads to the physical translocation of PKC from the cytoplasm to the sarcolemma, where it phosphorylates a substrate protein (possibly the ATP-sensitive K⁺ [K_ATP] channel⁴ ) and thereby confers resistance to ischemia. Support for this attractive hypothesis comes from a wealth of studies (most of which rely upon indirect evidence in the absence of PKC activity measurements) with activators and inhibitors of PKC or its translocation process, with receptor agonists and antagonists, and with agents . . . [Full Text of this Article]